KRIYA Ketamine Research Institute
is proud to present…
Conference for Ketamine Clinicians & Researchers
Nov. 7 & 8, 2015
9:30 AM – 5:00 PM
The Nueva School
Upper School Campus at Bay Meadows – 131 East 28th Ave – San Mateo, CA 94403
Featuring presentations by the leaders in this field, including Dr. Stephen Hyde, author of a new book on therapeutic ketamine
OBJECTIVES: The main agenda for this meeting is to share information about best clinical practices as it relates to ketamine treatment for depression, e.g., dose, frequency, inclusion criteria, exclusion criteria, long-term side effects, etc. There will be space to talk about our clinical successes and failures and puzzles, if you wish. In addition, we will start building a Ketamine Training Program for other physicians who want to learn about ketamine, and we will plan for our next two meetings (in 2016 and 2017).
ATTENDANCE: This conference is open to professionals who are currently working with ketamine in their clinical practices to treat depression (or other psychiatric disorders). It is also open to researchers who are studying ketamine to treat depression, or by invitation of the Event Organizer. This event is not open to the public.
REGISTRATION: Registration is now closed. There will be no on-site registration. For questions about registration, please contact please contact the Event Organizer at info@kriyainstitute.com. Conference fee is $395.00.
SCHEDULE:
Saturday
* Raquel Bennett, Psy.D. of San Mateo, CA – “Different Treatments for Different Patients”
* Terry Early, M.D. of Santa Barbara, CA – “Early Pioneering Work with Ketamine”
* Steven Levine, M.D. of Princeton, NJ – “Five Years and 500 patients… Thoughts on Treating Depression with Ketamine” (via Skype)
* Demitri Papolos, M.D. of Westport, CT – “Intranasal Ketamine for a Subgroup of Bipolar Children” (via Skype)
* Phil Wolfson, M.D. of San Francisco, CA – “Transformational Ketamine Practices”
* Bong Walsh, Ph.D. of Alameda, CA – “Antidepressant Effects of Ketamine and Proposed Mechanisms of Action”
* Stephen Hyde, M.D. of Tasmania, Australia – “Sublingual Ketamine… Safe, Effective, Affordable” (via Skype)
Sunday
* Rupert McShane, M.D. of Oxford, UK – “Experience of Ketamine Use in the First 700 Infusions” (via Skype)
* Francoise Bourzat, M.A. of San Francisco, CA – “Working with Spirit… High Dose Ketamine Treatments” (via Skype)
* Jon Berner, M.D. of Seattle, WA – “Chronic Therapeutic Ketamine Associates with Mitochondrial Changes in Humans”
* Bernard Wilcosky, M.D. of Redwood City, CA & Holly Happe, M.D. of Boston, MA & Makara Cayer of Boston, MA – “Ketamine in Anesthesiology”
* Angelo De Gioannis, M.D. of Brisbane, Australia – “Oral Augmentation… Is it a Viable Alternative?” (via Skype)
* Enrique Abreu, D.O. of Portland, OR – “Portland Ketamine Clinic”